S4906 Adalimumab-Induced Mania in a Crohn's Disease Patient: A Case Report

Introduction: Tumor necrosis factor-alpha (TNFα) inhibitors, including adalimumab, are widely used to manage autoimmune conditions like Crohn's disease. Although these agents generally have a favorable safety profile, emerging evidence links TNFα inhibitors to psychiatric side effects, particularly mood disturbances. Case Description/Methods: We present a case of a 19-year-old woman with Crohn's disease and no prior psychiatric history who developed a new-onset manic episode after starting adalimumab. The patient had no prior psychiatric history and exhibited agitation, hyperactivity, and religious preoccupation shortly after receiving 2 doses of adalimumab. Following discontinuation of the medication and psychiatric treatment, her symptoms resolved, and she remained stable for a year. Discussion: This case adds to the growing body of literature suggesting a potential link between TNFα inhibitors and manic episodes, highlighting the need for awareness and further research into their psychiatric effects.